Xeris RTU Glucagon Ph2 Results for Exercise-Induced Hypoglycemia

Xeris has announced positive topline results from the in-clinic stage of its Ph2 study of ready-to-use (RTU) glucagon for the prevention of exercise-induced hypoglycemia (EIH) in patients with T1DM. Below, FENIX provides context and insights on the results.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.